Matsui Kiyoshi, Sano Hajime
Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.
J Clin Med. 2017 Jul 5;6(7):65. doi: 10.3390/jcm6070065.
Primary Sjögren's syndrome is an autoimmune disease characterized by diffuse infiltration of lymphocytes into exocrine glands and other tissues. The infiltrating lymphocytes have been identified as subsets of B cells and T cells, including T helper 17 cells, T regulatory cells and follicular helper T cells. The role of these cells in the development of the syndrome is now known, as is their impact on the production of proinflammatory cytokines such as IL-6, IL-17, IL-22 and IL-23. In particular, experimental animal models and patients suggest that a shift in Th17/Treg balance toward the proinflammatory Th17 axis exacerbates primary Sjögren's syndrome and other autoimmune disorders. Nevertheless, the pathogenesis of the disorder is not yet fully elucidated. This review summarizes the recent advances in therapeutic control of the Treg/Th17 balance, as well as the efficacy of candidate therapeutics against primary Sjögren's syndrome.
原发性干燥综合征是一种自身免疫性疾病，其特征为淋巴细胞弥漫性浸润至外分泌腺和其他组织。浸润的淋巴细胞已被鉴定为B细胞和T细胞的亚群，包括辅助性T细胞17、调节性T细胞和滤泡辅助性T细胞。目前已知这些细胞在该综合征发展中的作用，以及它们对促炎细胞因子如白细胞介素-6、白细胞介素-17、白细胞介素-22和白细胞介素-23产生的影响。特别是，实验动物模型和患者表明，Th17/调节性T细胞平衡向促炎的Th17轴转变会加剧原发性干燥综合征和其他自身免疫性疾病。然而，该疾病的发病机制尚未完全阐明。本综述总结了调节性T细胞/辅助性T细胞17平衡治疗控制方面的最新进展，以及候选治疗药物对原发性干燥综合征的疗效。
